These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 23315167

  • 1. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
    Musallam KM, Taher AT, Cappellini MD, Sankaran VG.
    Blood; 2013 Mar 21; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA.
    Adv Pediatr; 1996 Mar 21; 43():309-34. PubMed ID: 8794181
    [No Abstract] [Full Text] [Related]

  • 3. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct 21; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 4. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A, Menzel S, Gupta R, Al-Sharida S, Farag A, Haider M, Akbulut N, Mustafa N, Thein SL.
    Am J Hematol; 2015 Jul 21; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract] [Full Text] [Related]

  • 5. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R, Hsieh MM, Zhao X, Calvaruso G, Rigano P, Renda D, Tisdale JF, Maggio A.
    Int J Mol Sci; 2018 Feb 28; 19(3):. PubMed ID: 29495591
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia.
    Atweh GF, Loukopoulos D.
    Semin Hematol; 2001 Oct 28; 38(4):367-73. PubMed ID: 11605172
    [Abstract] [Full Text] [Related]

  • 7. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
    Borg J, Phylactides M, Bartsakoulia M, Tafrali C, Lederer C, Felice AE, Papachatzopoulou A, Kourakli A, Stavrou EF, Christou S, Hou J, Karkabouna S, Lappa-Manakou C, Ozgur Z, van Ijcken W, von Lindern M, Grosveld FG, Georgitsi M, Kleanthous M, Philipsen S, Patrinos GP.
    Pharmacogenomics; 2012 Oct 28; 13(13):1487-500. PubMed ID: 23057549
    [Abstract] [Full Text] [Related]

  • 8. Hydroxyurea therapy in thalassemia.
    Loukopoulos D, Voskaridou E, Stamoulakatou A, Papassotiriou Y, Kalotychou V, Loutradi A, Cozma G, Tsiarta H, Pavlides N.
    Ann N Y Acad Sci; 1998 Jun 30; 850():120-8. PubMed ID: 9668534
    [Abstract] [Full Text] [Related]

  • 9. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.
    Lai ZS, Yeh TK, Chou YC, Hsu T, Lu CT, Kung FC, Hsieh MY, Lin CH, Chen CT, James Shen CK, Jiaang WT.
    Eur J Med Chem; 2021 Jan 01; 209():112938. PubMed ID: 33109398
    [Abstract] [Full Text] [Related]

  • 10. Hydroxycarbamide for sickle-cell anaemia in infancy.
    Weatherall DJ.
    Lancet; 2011 May 14; 377(9778):1628-30. PubMed ID: 21571132
    [No Abstract] [Full Text] [Related]

  • 11. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.
    Blood; 2002 Jan 01; 99(1):10-4. PubMed ID: 11756146
    [Abstract] [Full Text] [Related]

  • 12. DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O].
    Fathallah H.
    Clin Adv Hematol Oncol; 2008 Nov 01; 6(11):806-8. PubMed ID: 19194363
    [No Abstract] [Full Text] [Related]

  • 13. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.
    Acta Haematol; 1995 Nov 01; 94(3):128-34. PubMed ID: 7502628
    [Abstract] [Full Text] [Related]

  • 14. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
    Green NS, Barral S.
    Pediatr Res; 2014 Jan 01; 75(1-2):196-204. PubMed ID: 24252885
    [Abstract] [Full Text] [Related]

  • 15. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.
    J Pediatr; 1996 Jun 01; 128(6):820-8. PubMed ID: 8648542
    [Abstract] [Full Text] [Related]

  • 16. The role of hydroxyurea in sickle cell disease.
    Halsey C, Roberts IA.
    Br J Haematol; 2003 Jan 01; 120(2):177-86. PubMed ID: 12542474
    [No Abstract] [Full Text] [Related]

  • 17. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
    Ajanta H, Chakraborty S, Madhusnata D, Bhattacharya DK, Manisha D.
    J Assoc Physicians India; 2002 Aug 01; 50():1034-5. PubMed ID: 12421025
    [Abstract] [Full Text] [Related]

  • 18. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.
    Saunthararajah Y, DeSimone J.
    Semin Hematol; 2004 Oct 01; 41(4 Suppl 6):11-6. PubMed ID: 15534852
    [Abstract] [Full Text] [Related]

  • 19. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
    Sheehan VA, Luo Z, Flanagan JM, Howard TA, Thompson BW, Wang WC, Kutlar A, Ware RE, BABY HUG Investigators.
    Am J Hematol; 2013 Jul 01; 88(7):571-6. PubMed ID: 23606168
    [Abstract] [Full Text] [Related]

  • 20. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.
    Fibach E, Prasanna P, Rodgers GP, Samid D.
    Blood; 1993 Oct 01; 82(7):2203-9. PubMed ID: 7691251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.